Efficacy of Sofosbuvir and Daclatasvir Combination Treatment in Haemodialysis Patients with Chronic Hepatitis C

This study aimed to determine the effectiveness of the Sofosbuvir and Daclatasvir (SOF/DCV) combination treatment in haemodialysis patients with chronic hepatitis C virus (HCV). This prospective interventional study was conducted from October 2023 to April 2024. Sixty patients of either gender, aged 18 to 60 years, with chronic HCV infection who had been on haemodialysis for >3 months were included. All patients received a fixed dose of SOF/DCV. Sustained virologic response (SVR) was assessed three months after completion of therapy. The mean age of the patients was 45 ± 14.32 years, with 31 (51.7%) females and 29 (48.3%) males. SVR was achieved in all cases, indicating a 100% efficacy of SOF/DCV. Furthermore, no side effects were reported. Thus, combination of SOF/DCV is effective and safe for the treatment of HCV infection in haemodialysis patients.